Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,146
- Phase 21,063
- Phase 1820
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis140
- Type 1 Diabetes134
- Atopic Dermatitis130
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections113
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland195
- Alabama176
- Florida145
- Arizona141
- New York122
- Massachusetts119
- Texas118
- Illinois81
- Colorado76
Recruiting studies6,230 total
- NCT07562542Recruiting
Blood test study for mastocytosis mutation detection
This study looks for a specific genetic change (KIT-D816V mutation) in the blood of adults with mast cell disorders—conditions where immune cells called mast cells cause allergic-like reactions. Understanding this mutation may help doctors better diagnose and treat your condition.
Suzhou, JiangsuAges 18 years+ - NCT07564219Recruiting
Beta-Hydroxybutyrate to Boost CAR-T Cell Therapy in Multiple Myeloma
This trial tests whether a natural metabolite called beta-hydroxybutyrate can strengthen CAR-T cell therapy (a type of cancer-fighting cell treatment) in multiple myeloma patients. The goal is to help your immune cells work better against your cancer.
Hamburg, Free and Hanseatic City of HamburgAges 18 years+ - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65 - NCT07564752Recruiting
How Better Blood Sugar Control Affects Cholesterol in Type 1 Diabetes
This study compares how blood fats (especially HDL cholesterol) differ between people with well-controlled type 1 diabetes and people without diabetes. Researchers want to understand if improving blood sugar control can help improve these protective blood fats.
DijonAges 18 years+ - NCT07566377RecruitingPhase 2
Cord Blood Transplant for Children and Young Adults With Blood Cancer
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
New York, New YorkAges Up to 26 years - NCT07566351RecruitingPhase 2
Add-On Drugs for Rheumatoid Arthritis
This study tests whether two drugs—roflumilast and desloratadine—added to your current rheumatoid arthritis medications can reduce joint inflammation and pain. You'd take these as add-ons to your existing treatment to see if they help control your disease better.
Damietta, Damietta GovernorateAges 18–60 - NCT07568028Recruiting
Physical Activity in Teens With Type 1 Diabetes
This study explores why some teenagers with type 1 diabetes are more active than others. Researchers want to understand the personal, social, and environmental factors that affect exercise habits, which may help improve health outcomes for teens managing diabetes.
Istanbul, ZeytinburnuAges 9–18 - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07570745RecruitingPhase 2
Stem cell transplant with new drugs to prevent GVHD
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07571993Recruiting
Tracking Rheumatoid Arthritis Remission and Treatment Changes
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
Pavia, PaviaAges 18 years+ - NCT07572669RecruitingPhase 2
Moxibustion for Steroid-Resistant Graft-Versus-Host Disease
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
Wuhan, HubeiAges 14–65 - NCT07573228Recruiting
Obesity's effect on insulin action and fitness in Type 1 Diabetes
This study examines how excess weight affects how insulin works in small blood vessels and overall fitness in people with Type 1 Diabetes. Researchers want to understand if obesity makes diabetes management harder and whether this knowledge can help future treatments.
Charlottesville, VirginiaAges 21–50 - NCT07573735Recruiting
Blood markers and skin inflammation in atopic dermatitis
This study examines a specific blood marker (cfDNA-STING) that may help explain why atopic dermatitis develops. Researchers will compare this marker in people with and without atopic dermatitis to understand the condition better.
Nanjing, JiangsuAges 18 years+ - NCT07575347Recruiting
Gum Disease and Rare Kidney Disorders Study
This study explores whether people with certain rare kidney diseases or chronic kidney problems have more gum disease than others. Researchers will examine your teeth and gums to understand the connection and help improve care for people with kidney conditions.
BucharestAges 18 years+ - NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07577206RecruitingEarly Phase 1
New PET Scan Tracer for Advanced Solid Cancers
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Naples, ItaliaAges 18 years+ - NCT07578584RecruitingPhase 1
Safety study of NNC0497-0040 in healthy and overweight adults
This early-stage study tests a new investigational medication in three groups: healthy adults with normal weight, adults who are overweight or obese, and men with type 1 diabetes who are also overweight. The research aims to understand how safe the medication is and how the body processes it.
NeussAges 18–55 - NCT07578675Recruiting
Brain Activity Patterns in Anemia Patients
This study uses a non-invasive brain imaging tool to understand how anemia affects thinking and brain function. Researchers hope to learn more about why some anemia patients experience cognitive problems and how to help them.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT07580820Recruiting
Walking Adaptability in Early-Stage Multiple Sclerosis
This study looks at how people with mild multiple sclerosis (MS) adapt their walking and balance. Researchers will test your walking ability and how your body adjusts to different movements, which could help improve care for people with MS.
DiepenbeekAges 18–65 - NCT07581704RecruitingPhase 1
Sirolimus plus immunotherapy for relapsed multiple myeloma
This study tests whether a drug called sirolimus, given before certain immunotherapy treatments (teclistamab or talquetamab), helps these treatments work better against multiple myeloma. These immunotherapies teach your immune cells to attack myeloma cells.
Iowa City, IowaAges 18 years+ - NCT07582354Recruiting
Understanding Multiple Myeloma Differences Between Patients
This study collects information and samples from people with multiple myeloma or related blood disorders to understand why the disease affects people differently. Researchers will use this information to develop better, personalized treatment approaches.
Bologna, BoAges 18 years+ - NCT07582432RecruitingPhase 3
Gamunex for Blood Cancer Patients With Low Antibodies
This trial tests whether Gamunex, an antibody replacement therapy, helps patients with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma who have low immunoglobulin (antibody) levels. The treatment may reduce infections and improve how well the body fights disease.
St. Petersburg, FloridaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,786 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.